pretickt

Is BAX a good stock to buy?

Baxter International Inc. · end-of-day data as of Nov 13, 2026

Baxter
BAX · $13.35B
$25.81+0.3%
Nov 13, 2026 · close
$24$26SepOctNov9:3016:003 months -0.5%Nov 13 · close
▲ 4
  • FCF yield+7.5%
  • MAs4 of 4
  • MACD0.07
  • Sector▲ +15.9%
Neutral
  • Earnings in90d
  • RSI54
  • Support-5.7%
  • Resistance+0.1%
  • Off 52w high-14.0%
  • Volume0.6x
  • Bollingerupper half
  • News0.00
  • ConsensusHold · 15
  • Trendsideways
  • 52w range$16–$30
  • ATR+3.8%
  • Off ATH-72.9%
  • InsidersNone in 90d
▼ 1
  • PT$22.25 -13.8%

Updates with the 15-min delayed price. Not a forecast or investment advice.

Is Baxter a good stock to buy?

Baxter is strong on 1 of the 5 questions about the business; weak on demand, advantage and economics. With a loss over the last 12 months, Baxter has no P/E ratio (Nov 13, 2026). pretickt does not say whether to buy or sell.

  1. Demand shrinking
  2. Advantage easy to copy
  3. Economics losing money
  4. Execution mixed
  5. Fragility sturdy
  6. Price below its peers
DemandDo people want more of what it sells?shrinking

BAX sales growth revenue growth

-9%a year, for the last 3 years

Baxter's sales fell 9% a year for 3 years, to $11.24B in fiscal 2025.

BAX analysts' forecast revenue estimates

+4%the sales they expect next fiscal year, on the last

Analysts expect Baxter's sales to grow 4% to $11.72B in fiscal 2026 (11 analysts).

BAX competitors

pretickt analysis+5%its sales in 12 months, on a year before

Baxter's sales grew 5% in the 12 months to Sep 30, 2026, faster than Cooper Companies (+5%) and Solventum (-3%), slower than West Pharmaceutical Services (+13%) and ResMed (+9%).

BAX sales by business revenue by segment

49%of its sales from Medical Products And Therapies

Medical Products And Therapies brought Baxter 49% of its sales in fiscal 2025; Healthcare Systems and Technologies 28%.

Advantage moatIs it hard to copy?easy to copy

BAX return on capital ROIC

pretickt analysis-2%earned before tax on the money invested in it

Baxter earned -2% before tax on the capital invested in it in the 12 months to Sep 30, 2026; ResMed 34%, West Pharmaceutical Services 28%, Solventum 21% and Cooper Companies 5%.

BAX margin on each sale gross margin

30%left after making the product

Baxter kept 30% of each sale after making the product in the 12 months to Sep 30, 2026; its competitors' median is 58%.

EconomicsDoes it make good money?losing money

BAX margin after costs profit margin

-2%of sales left after running the business

Baxter's operating margin was -2% in the 12 months to Sep 30, 2026, against -14% in fiscal 2022.

BAX cash generated free cash flow

$1Bcash left after investing, last 12 months

Baxter generated $1B of free cash flow in the 12 months to Sep 30, 2026, while it reported a loss.

ExecutionDoes it deliver what it promises?mixed

BAX earnings vs estimates

6 of 8quarters above the analysts' estimate

Baxter beat the analysts' profit estimate in 6 of its last 8 quarters, the latest on Oct 29, 2026.

BAX number of employees

-1%fewer people in a year

Baxter had 37,500 employees at the end of fiscal 2025, 1% fewer than a year before.

BAX CEO pay

$7.67Mfor fiscal 2025, 0% of it in stock and options

Baxter paid its CEO $7.67M for fiscal 2025, 0% of it in stock and options.

Fragility risksCould something break it?sturdy

BAX financial health Altman Z-score

2.4Altman Z-score, safe above 3

Baxter's Altman Z-score is 2.4 (Nov 13, 2026), between 1.8 and 3, the grey zone.

BAX quality checks Piotroski score

4 of 9checks passed

Baxter passes 4 of the 9 Piotroski checks in the 12 months to Sep 30, 2026; it misses on profit, return on assets, the current ratio, new shares and gross margin.

BAX in past recessions

pretickt analysis+2%its sales in the worst one

Baxter's sales grew through each of the last 2 US recessions (2008–09 and 2020).

Price valuationIs the price reasonable?below its peers

BAX price vs profit P/E ratio

—it lost money in 12 months: no P/E

Baxter has no P/E ratio: it lost money over the 12 months to Sep 30, 2026.

BAX price vs assets price to book

2.1×times what its assets are worth on paper

Baxter trades at 2.1 times its book value (Nov 13, 2026); its competitors' median is 4.4.

BAX analysts' target price target

-14%to their average target

Analysts' average price target for Baxter is $22.25, 14% below the Nov 13, 2026 close of $25.81.

BAX growth priced in fair value

pretickt analysis+1%a year, for ten years, to be worth the price

At $25.81 a share, Baxter's free cash flow must grow about 1% a year for ten years to be worth the price (Nov 13, 2026).

What is Baxter's P/E ratio?

Baxter has no P/E ratio: it lost money over the 12 months to Sep 30, 2026. Baxter trades at 2.1 times its book value (Nov 13, 2026); its competitors' median is 4.4.

Who are Baxter's biggest competitors?

pretickt compares Baxter with Cooper Companies, Solventum, West Pharmaceutical Services and ResMed. Baxter's sales grew 5% in the 12 months to Sep 30, 2026, faster than Cooper Companies (+5%) and Solventum (-3%), slower than West Pharmaceutical Services (+13%) and ResMed (+9%).

Is Baxter profitable?

Baxter's operating margin was -2% in the 12 months to Sep 30, 2026, against -14% in fiscal 2022. Baxter generated $1B of free cash flow in the 12 months to Sep 30, 2026, while it reported a loss.

How does Baxter make money?

Medical Products And Therapies brought Baxter 49% of its sales in fiscal 2025; Healthcare Systems and Technologies 28%.

How many employees does Baxter have?

Baxter had 37,500 employees at the end of fiscal 2025, 1% fewer than a year before.

From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.